Opko Health Inc (OPK)

[game7alcs]

Opko would be meeting with the FDA in Q1 2017 to discuss the results and potential for BLA [Biologics License Application] submission based on a modified statistical plan that excludes outliers. The analyst noted that variables such as exercise regimen and diet would likely be included in any modified statistical analysis. The FDA could ask the company to undertake another Phase III study that may need 2.5 years to complete. Sell-Off Overdone DeGeeter stated that the ~20 percent selloff presented an opportunity to buy Opko's shares, while mentioning the following reasons: Expectation for positive pediatric hGH Phase III data Roughly 80 percent of potential economics from the hGH program was associated with the pediatric indication The company had multiple other product launches in 2017